What diseases or conditions do Gilead's products target?

Gilead Sciences is a biopharmaceutical company that focuses on the discovery, development, and commercialization of innovative therapies for various diseases and conditions. Some of the key therapeutic areas that Gilead targets include infectious diseases, particularly viral infections such as HIV, hepatitis B, and hepatitis C. Gilead is well-known for its contributions to HIV treatment and prevention, having developed several antiretroviral therapies that have significantly improved the quality of life for individuals living with HIV. In addition to infectious diseases, Gilead also addresses conditions related to respiratory diseases, particularly those caused by viral infections. Gilead has developed medications for influenza and has been involved in research related to other respiratory viruses. Furthermore, Gilead has expanded its research efforts into oncology, focusing on various types of cancers, including hematologic malignancies. The company is invested in developing targeted therapies and immunotherapies that can effectively address these malignancies. Moreover, Gilead's commitment to solving unmet medical needs has led to investigations in other therapeutic areas, including inflammatory diseases and certain genetic disorders. For the most accurate and up-to-date information on Gilead Sciences and the specific products that target these diseases, it may be helpful to explore their official website, where product information and therapeutic areas are frequently updated.